Vnitr Lek 2023, 69(6):373-379 | DOI: 10.36290/vnl.2023.073

FENO potential in asthma

Petr Čáp
Centrum alergologie a klinické imunologíe, Nemocnice Na Homolce, Praha

Mechanisms of FENO production in epithelial cells in the area lower airways is being resumed. The author focuses on usage of this biomarker in clinical practice and with respect to new established upcoming biological treatment just in severe variants of the disease. Recent publications of FENO are analysed in omalizumab and other types of biological treatment such as mepolizumab and reslizumab, concentrated on IL-5 or receptor for IL-5 benralizumab. They have been approved as an additional treatment of severe refractory eosinophilic adult asthma. FENO as a marker of asthma influenceable by biological treatment can be used to evaluate the efficiency of therapy and it is mainly suitable in dupilumab (anti-IL-4 and 13) and the latest in tezepelumab (anti-TSLP). The biological treatment focused on IL-5 reduces eosinophilic inflammation, however has a limited influence to activate epithelial cells where FENO is being created. The cost to benefit ratio of FENO is advantageous and this biomarker in combination with other clinical assessment improves asthma treatment.

Keywords: FENO, asthma, biological treatment.

Accepted: September 21, 2023; Published: October 10, 2023  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Čáp P. FENO potential in asthma. Vnitr Lek. 2023;69(6):373-379. doi: 10.36290/vnl.2023.073.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Teřl M, Sedlák V, Krčmová I. Doporučený postup diagnostiky a léčby těžkého astmatu. GEUM 2023. ISBN 978-80-87969-64-9.
    2. Murugesan N, Saxena D, Dileep A, Adrish, et al. Update on the Role of FeNO in Asthma Management. Diagnostics. 2023(13):1428. Go to original source... Go to PubMed...
    3. Mormile M, Mormile I, Fuschillo S, et al. Eosinophilic Airway Diseases: From Pathophysiological Mechanisms to Clinical Practice. Int J Mol Sci. 2023;24(8):7254. Go to original source... Go to PubMed...
    4. Dweik RA, Boggs PB, Erzurum SC. et al. American Thoracic Society Committee on Interpretation of Exhaled Nitric Oxide Levels (FENO) for Clinical Applications. An official ATS clinical practice guideline: interpretation of exhaled nitric oxide levels (FENO) for clinical applications. Am J Respir Crit Care Med. 2011;184:602-615. Go to original source... Go to PubMed...
    5. National Institute for Health and Care Excellence (NICE). Asthma: Diagnosis, Monitoring and Chronic Asthma Management. London: NICE; 2017. www.nice.org.uk/guidance/ng80
    6. Guida G, et al. Critical evaluation of asthma biomarkers in clinical practice." Frontiers in medicine vol. 9 969243. 10, 2022, doi:10.3389/fmed.2022.969243 Go to original source... Go to PubMed...
    7. Fouka, Evangelia, et al. Recent insights in the role of biomarkers in severe asthma management. Frontiers in medicine vol. 9 992565.26,2022. Go to original source... Go to PubMed...
    8. Hanania NA, Wenzel S, Rosén K, et al. Exploring the effects of omalizumab in allergic asthma: an analysis of biomarkers in the EXTRA study. Am J Respir Crit Care Med. 2013; 187:804-811. Go to original source... Go to PubMed...
    9. Casale TB, Luskin AT, Busse W, et al. Omalizumab effectiveness by biomarker status in patients with asthma: evidence from PROSPERO, a prospective real­‑world study. J Allergy Clin Immunol Pract. 2019;7:156-164.e1. Go to original source... Go to PubMed...
    10. Shrimanker R, Keene O, Hynes G, Wenzel S, Yancey S, Pavord ID. Prognostic and predictive value of blood eosinophil count, fractional exhaled nitric oxide, and their combination in severe asthma: a post hoc analysis. Am J Respir Crit Care Med. 2019;200:1308-1312. Go to original source... Go to PubMed...
    11. Hearn AP, Kavanagh J, d'Ancona G. et al. The relationship between FENO and effectiveness of mepolizumab and benralizumab in severe eosinophilic asthma. J Allergy Clin Immunol Pract. 2021;9:2093-2096.e1 Go to original source... Go to PubMed...
    12. Wenzel S, Castro M, Corren J, et al. Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium­‑to­‑high­‑dose inhaled corticosteroids plus a long­‑acting β2 agonist: a randomised double­‑blind placebo­‑controlled pivotal phase 2 b dose­‑ranging trial. Lancet. 2016;388(10039):31-44. Go to original source... Go to PubMed...
    13. Castro M, Corren J, Pavord ID, et al. Dupilumab efficacy and safety in moderate­‑to­‑severe uncontrolled asthma. N Engl J Med. 2018;378:2486-2496. Go to original source... Go to PubMed...
    14. Rabe KF, Nair P, Brusselle G, et al. Efficacy and safety of dupilumab in glucocorticoid­‑dependent severe asthma. N Engl J Med. 2018;378:2475-2485. Go to original source... Go to PubMed...
    15. Menzies­‑Gow A, Corren J, Bourdin A, et al. Tezepelumab in adults and adolescents with severe, uncontrolled asthma. N Engl J Med. 2021;384:1800-1809. Go to original source... Go to PubMed...
    16. Corren J, Parnes JR, Wang L, et al. Tezepelumab in adults with uncontrolled asthma. N Engl J Med. 2017;377:936-946. Go to original source... Go to PubMed...
    17. Couillard, Simon et al. Toward a Predict and Prevent Approach in Obstructive Airway Diseases. JACI in practice. 2023(11,3):704-712. Go to original source... Go to PubMed...
    18. Petsky, Helen L, et al. Tailoring asthma treatment on eozinophilic markers (FENO or sputum eosinophils): a systematic review and meta­‑analysis. Thorax. 2018;12:1110-1119. Go to original source... Go to PubMed...
    19. Petusi N, et al. Measutŕing lung function in airway disease s\\. current and emerging techniques. Thorax. 2019;74,795-805. Go to original source... Go to PubMed...
    20. Heaney LG, Busby J, Bradding P, et al. Medical Research Council UK Refractory Asthma Stratification Programme (RASP­‑UK). Remotely Monitored Therapy and Nitric Oxide Suppression Identifies Nonadherence in Severe Asthma. Am J Respir Crit Care Med. 2019;199:454-464. Go to original source... Go to PubMed...

    Return to the content


    Vnitřní lékařství

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.